The trial reportedly did not meet its primary endpoint of superiority in extending progression free survival (PFS).
Pfizer Oncology Business Unit senior vice president of clinical development and medical affairs Mace Rothenberg said the trial advances their knowledge about the role and limitations of combining targeted therapies in the treatment of advanced RCC.
"Additional analyses will be performed to help us understand this result," Rothenberg added.
"The study outcome, involving combination therapy, does not change the safety and efficacy relationship of single-agent TORISEL for advanced RCC patients with a poor prognostic risk profile."
About 13,000 individuals die of this tumor in the US every year, according to Pfizer.
l